磷虾油治疗膝骨关节炎:一项随机临床试验
该多中心、随机、双盲、安慰剂对照试验在澳大利亚5个城市纳入262例有显著膝痛且MRI显示积液-滑膜炎的临床膝骨关节炎患者,随机接受磷虾油2 g/d(n=130)或匹配安慰剂(n=132)治疗24周。结果显示磷虾油与安慰剂相比未改善膝痛(VAS评分均值变化 -19.9 vs -20.2;组间均值差 -0.3;95%CI -6.9至6.4)。作者结论认为这些发现不支持在该人群中用磷虾油治疗膝痛。
要点
- 在显著膝痛且MRI显示积液-滑膜炎的膝骨关节炎患者中,磷虾油2 g/d治疗24周未改善膝痛。
- VAS膝痛评分均值变化磷虾油组 -19.9 vs 安慰剂组 -20.2,组间均值差 -0.3(95%CI -6.9至6.4)。
- 不良事件报告率磷虾油组51%(67/130)vs 安慰剂组54%(71/132),最常见为肌肉骨骼与结缔组织疾病。
核心结论
- 在有显著膝痛且MRI显示积液-滑膜炎的膝骨关节炎患者中,每日补充磷虾油2 g/d治疗24周与安慰剂相比未改善膝痛。
- 作者结论认为这些发现不支持在该人群中用磷虾油治疗膝痛。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验,在澳大利亚5个城市开展。
- 纳入临床膝骨关节炎、有显著膝痛且磁共振成像显示积液-滑膜炎的参与者,入组时间为2016年12月至2019年6月,末次随访于2020年2月7日。
- 参与者随机接受磷虾油2 g/d(n=130)或匹配安慰剂(n=132)治疗24周。
- 共随机262例参与者(平均年龄61.6岁,标准差9.6;女性53%),222例(85%)完成试验。
主要发现
- 主要结局为24周内膝痛视觉模拟量表(VAS,范围0-100,0表示最轻疼痛,最小临床重要改善为15)评分变化。
- 磷虾油与安慰剂相比未改善膝痛:VAS评分均值变化 -19.9(磷虾油组)vs -20.2(安慰剂组);组间均值差 -0.3;95%CI -6.9至6.4。
- 至少报告1项不良事件者:磷虾油组51%(67/130)vs 安慰剂组54%(71/132)。
- 最常见不良事件为肌肉骨骼与结缔组织疾病,磷虾油组发生32次 vs 安慰剂组42次,包括膝痛(磷虾油组n=10;安慰剂组n=9)、下肢痛(磷虾油组n=1;安慰剂组n=5)和髋痛(磷虾油组n=3;安慰剂组n=2)。
关键数值与推荐
- VAS评分最小临床重要改善为15(范围0-100,0表示最轻疼痛)。
- 磷虾油组VAS评分均值变化 -19.9 vs 安慰剂组 -20.2;组间均值差 -0.3;95%CI -6.9至6.4。
- 至少1项不良事件:磷虾油组51%(67/130)vs 安慰剂组54%(71/132)。
临床怎么用
- 作者结论认为这些发现不支持在该人群(有显著膝痛且MRI显示积液-滑膜炎的膝骨关节炎患者)中用磷虾油治疗膝痛。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Knee osteoarthritis is disabling, with few effective treatments. Preliminary evidence suggested that krill oil supplementation improved knee pain, but effects on knee osteoarthritis remain unclear. OBJECTIVE: To evaluate efficacy of krill oil supplementation, compared with placebo, on knee pain in people with knee osteoarthritis who have significant knee pain and effusion-synovitis. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled clinical trial in 5 Australian cities. Participants with clinical knee osteoarthritis, significant knee pain, and effusion-synovitis on magnetic resonance imaging were enrolled from December 2016 to June 2019; final follow-up occurred on February 7, 2020. INTERVENTIONS: Participants were randomized to 2 g/d of krill oil (n = 130) or matching placebo (n = 132) for 24 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change in knee pain as assessed by visual analog scale (range, 0-100; 0 indicating least pain; minimum clinically important improvement = 15) over 24 weeks. RESULTS: Of 262 participants randomized (mean age, 61.6 [SD, 9.6] years; 53% women), 222 (85%) completed the trial. Krill oil did not improve knee pain compared with placebo (mean change in VAS score, -19.9 [krill oil] vs -20.2 [placebo]; between-group mean difference, -0.3; 95% CI, -6.9 to 6.4) over 24 weeks. One or more adverse events was reported by 51% in the krill oil group (67/130) and by 54% in the placebo group (71/132). The most common adverse events were musculoskeletal and connective tissue disorders, which occurred 32 times in the krill oil group and 42 times in the placebo group, including knee pain (n = 10 with krill oil; n = 9 with placebo), lower extremity pain (n = 1 with krill oil; n = 5 with placebo), and hip pain (n = 3 with krill oil; n = 2 with placebo). CONCLUSIONS AND RELEVANCE: Among people with knee osteoarthritis who have significant knee pain and effusion-synovitis on magnetic resonance imaging, 2 g/d of daily krill oil supplementation did not improve knee pain over 24 weeks compared with placebo. These findings do not support krill oil for treating knee pain in this population. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12616000726459; Universal Trial Number: U1111-1181-7087.
引用
- Laslett LL, Scheepers LEJM, Antony B, et al. Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2024. PMID: 38776073. doi:10.1001/jama.2024.6063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。